olaparib tablets,
for oral use Initial U.S. Approval: 2014
As specified in the prescribing information, olaparib tablets is indicated for the treatment of Ovarian cancer and Breast cancer. Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer and Breast cancer.
Facts about olaparib tablets
Approval Date: 2014
Proprietary Name: LYNPARZA (olaparib) tablets
Active Ingredient(s): olaparib
FDA-approved use: Ovarian cancer and Breast cancer.
Dosage Form: Tablets: 150 mg, 100 mg
Medicine Approved By: US FDA
Manufacturer: AstraZeneca
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “olaparib tablets” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
info@indianpharmanetwork.co.in
FAX NUMBER:
+91-11-26532129
Query For olaparib tablets
Approved accessible "olaparib tablets"
Lynparza (olaparib) tablets, which were first approved in 2014, were approved in 2022 for the adjuvant treatment of adults with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who were previously treated with (neo)adjuvant chemotherapy.
How can 1 go about obtaining olaparib tablets?
If olaparib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
LYNPARZA (olaparib) tablets, for oral use Initial U.S. Approval: 2014
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in